Timing of Re-evaluation After Steps I-II of Periodontal Therapy

Sponsor
University of Turin, Italy (Other)
Overall Status
Recruiting
CT.gov ID
NCT05892315
Collaborator
(none)
60
1
2
12
5

Study Details

Study Description

Brief Summary

Literature on non surgical periodontal therapy (NSPT) shows lack of clarity in reporting information on re-evaluation timing and clinical response. If the re-evaluation was done shortly after NSPT, this is also likely to have an influence on the surgical treatment plan. The aim of this randomized clinical trial is to investigate the effect of re-evaluation timing at 1-3-6 months after NSPT in terms of pocket closure, probing pocket depth reduction, comprehensive treatment plan, and costs for the patient.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Repeated subgingival instrumentation
  • Procedure: Supragingival scaling
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Timing of Re-evaluation After Steps I-II of Periodontal Therapy: a Randomized Clinical Trial
Actual Study Start Date :
May 11, 2023
Anticipated Primary Completion Date :
Dec 11, 2023
Anticipated Study Completion Date :
May 11, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Repeated subgingival instrumentation

Conventional staged debridement (CSD) according to the severity of periodontitis in 2 to 4 appointments at day 0, 7, 14 and 21. Re-instrumentation at 6 weeks and 3 months after completion of step I-II.

Procedure: Repeated subgingival instrumentation
Supragingival scaling will be performed at sites with plaque and subgingival scaling will be performed by the use of manual and ultrasonic instruments at pockets ≥ 4 mm with bleeding. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.

Active Comparator: Supragingival instrumentation

Conventional staged debridement (CSD) according to the severity of periodontitis in 2 to 4 appointments at day 0, 7, 14 and 21. Only supragingival instrumentation at 6 weeks and 3 months after completion of step I-II.

Procedure: Supragingival scaling
Supragingival scaling will be performed at sites with plaque. Oral hygiene instructions will be reinforced. Patients will be instructed to use interdental brushes with appropriate size interdental brushes or dental floss when interdental embrasures will not allow for interdental brushing.

Outcome Measures

Primary Outcome Measures

  1. Change in treatment success % (0 - 100 % with higher percentage indicating better status) [Baseline, 1 month, 3 months and 6 months after the completion of the therapy.]

    Percentage of pockets ≥ 4 mm with bleeding that converted to ≤ 3 mm or ≤4 mm without bleeding at the completion of non-surgical periodontal therapy

Secondary Outcome Measures

  1. Change in Full Mouth Plaque Score (FMPS%) (0 - 100 % with higher percentage indicating worse status) [Baseline, 1 month, 3 months and 6 months after the completion of the therapy.]

    Percentage of full mouth plaque score considering 6 sited for each tooth.

  2. Change in Probing Pocket Depth (PD) (0 - 15 mm with higher values indicating worse outcomes). [Baseline, 1 month, 3 months and 6 months after the completion of the therapy.]

    The distance between the cementoenamel junction (CEJ) and the base of the pocket.

  3. Change in Clinical Attachment Level (CAL) (0 - 15 mm with higher values indicating worse outcomes). [Baseline, 1 month, 3 months and 6 months after the completion of the therapy.]

    The sum of Probing pocket depth (PD, mm) and Recession (Rec, mm).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Periodontitis stage III-IV

  • Full-mouth plaque score (FMPS) < 25% at the 1-month re-evaluation

  • Full-mouth bleeding score (FMBS) < 25% at the 1-month re-evaluation

  • Signed informed consent

Exclusion criteria:
  • Age < 18 yo

  • Pregnancy or lactation

  • Heavy smokers (>10 die)

  • Conditions or diseases influencing periodontal healing

  • Patients that cannot complete the 6 months follow-up

Contacts and Locations

Locations

Site City State Country Postal Code
1 CIR Dental School Turin Italy 10126

Sponsors and Collaborators

  • University of Turin, Italy

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Turin, Italy
ClinicalTrials.gov Identifier:
NCT05892315
Other Study ID Numbers:
  • UTurin3
First Posted:
Jun 7, 2023
Last Update Posted:
Jun 7, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 7, 2023